Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia

被引：6

作者：

Kinjyo, Ichiko ^{[1
]}

Matlawska-Wasowska, Ksenia ^{[2
,3
]}

Chen, Xiaoru ^{[4
]}

Monks, Noel R. ^{[5
]}

Burke, Patricia ^{[4
]}

Winter, Stuart S. ^{[2
,3
]}

Wilson, Bridget S. ^{[1
,2
]}

机构：

[1] Univ New Mexico, Dept Pathol, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[2] Univ New Mexico, Ctr Canc, Hlth Sci Ctr, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Div Hematol Oncol, Albuquerque, NM 87131 USA

[4] MedImmune, Translat Med Oncol, Gaithersburg, MD USA

[5] MedImmune, Oncol Res, Gaithersburg, MD USA

来源：

PEDIATRIC BLOOD & CANCER | 2017年 / 64卷 / 11期

关键词：

acute lymphoblastic leukemia; immunotherapy; HEMATOLOGIC MALIGNANCIES; PSEUDOMONAS EXOTOXIN; IMMUNOTOXIN; CAT-8015; TRIAL; HA22; CD22;

D O I：

10.1002/pbc.26604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Moxetumomab pasudotox is a second-generation recombinant immunotoxin against CD22 on B-cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy-refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient-derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD-scid IL2Rg(null) mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient-derived xenograft models.

引用

页数：4

共 12 条

[1] CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Alderson, Ralph F.
Kreitman, Robert J.
Chen, Tianling
Yeung, Peter
Herbst, Ronald
Fox, Judy A.
Pastan, Ira
[J]. CLINICAL CANCER RESEARCH, 2009, 15 (03) : 832 - 839
[2] Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, Waleed
Lee, Daniel W.
Shah, Nirali N.
Stetler-Stevenson, Maryalice
Yuan, Constance M.
Pastan, Ira H.
Dimitrov, Dimiter S.
Morgan, Richard A.
FitzGerald, David J.
Barrett, David M.
Wayne, Alan S.
Mackall, Crystal L.
Orentas, Rimas J.
[J]. BLOOD, 2013, 121 (07) : 1165 - 1174
[3] Anti-CD22 therapy in acute lymphoblastic leukaemia
Hoelzer, Dieter
[J]. LANCET ONCOLOGY, 2012, 13 (04) : 329 - 331
[4] Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Hunger, Stephen P.
Lu, Xiaomin
Devidas, Meenakshi
Camitta, Bruce M.
Gaynon, Paul S.
Winick, Naomi J.
Reaman, Gregory H.
Carroll, William L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1663 - 1669
[5] Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Kreitman, Robert J.
Tallman, Martin S.
Robak, Tadeusz
Coutre, Steven
Wilson, Wyndham H.
Stetler-Stevenson, Maryalice
FitzGerald, David J.
Lechleider, Robert
Pastan, Ira
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1822 - 1828
[6] Development and Scale-Up of a Commercial Fed Batch Refolding Process for an Anti-CD22 Two Chain Immunotoxin
Linke, Thomas
Aspelund, Matthew T.
Thompson, Christopher
Xi, Guoling
Fulton, Andrew
Wendeler, Michaela
Pabst, Timothy M.
Wang, Xiangyang
Wang, William K.
Ram, Kripa
Hunter, Alan K.
[J]. BIOTECHNOLOGY PROGRESS, 2014, 30 (06) : 1380 - 1389
[7] Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia
Mussai, Francis
Campana, Dario
Bhojwani, Deepa
Stetler-Stevenson, Maryalice
Steinberg, Seth M.
Wayne, Alan S.
Pastan, Ira
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) : 352 - 358
[8] Characterization of CD22 Expression in Acute Lymphoblastic Leukemia
Shah, Nirali N.
Stevenson, Maryalice Stetler
Yuan, Constance M.
Richards, Kelly
Delbrook, Cindy
Kreitman, Robert J.
Pastan, Ira
Wayne, Alan S.
[J]. PEDIATRIC BLOOD & CANCER, 2015, 62 (06) : 964 - 969
[9] Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
Sullivan-Chang, Loretta
O'Donnell, Robert T.
Tuscano, Joseph M.
[J]. BIODRUGS, 2013, 27 (04) : 293 - 304
[10] Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Wayne, Alan S.
Kreitman, Robert J.
Findley, Harry W.
Lew, Glen
Delbrook, Cynthia
Steinberg, Seth M.
Stetler-Stevenson, Maryalice
FitzGerald, David J.
Pastan, Ira
[J]. CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1894 - 1903

← 1 2 →